Comparative Pharmacology
Head-to-head clinical analysis: SINEQUAN versus TOFRANIL PM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SINEQUAN versus TOFRANIL PM.
SINEQUAN vs TOFRANIL-PM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits reuptake of serotonin and norepinephrine in the CNS; also has anticholinergic, antihistaminergic, and sedative effects.
Tofranil-PM (imipramine pamoate) is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin from the synaptic cleft, increasing their concentrations in the central nervous system. It also has anticholinergic, antihistaminergic, and alpha-1 adrenergic blocking effects.
Initial: 50-150 mg/day PO divided 1-3 times daily; max 300 mg/day. Maintenance: lowest effective dose.
100-200 mg orally once daily at bedtime, starting at 25-50 mg/day and titrating up by 25-50 mg every 2-3 weeks. Maximum 300 mg/day.
None Documented
None Documented
Terminal elimination half-life: 8–24 hours (parent drug); steady state achieved in 2–4 weeks; clinical context: may require dose adjustment in hepatic impairment.
Terminal elimination half-life: 8-30 hours (mean 21 hours); clinical context: steady-state reached in 5-7 days; extended half-life in elderly and hepatic impairment.
Renal (approximately 30-40% as unchanged drug, with extensive hepatic metabolism to metabolites; minor biliary/fecal excretion).
Renal: 40-70% as metabolites; biliary/fecal: 20-30%; unchanged drug: <5%.
Category C
Category C
Tricyclic antidepressant
Tricyclic antidepressant